| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | New England Journal of Medicine | 2015 | 5.6K |
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | New England Journal of Medicine | 2015 | 5.5K |
| Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | New England Journal of Medicine | 2015 | 3.7K |
| PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma | New England Journal of Medicine | 2015 | 2.5K |
| Immune checkpoint blockade: a common denominator approach to cancer therapy | Cancer Cell | 2015 | 2.4K |
| The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints | Cancer Discovery | 2015 | 890 |
| Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses | Cell | 2015 | 872 |
| Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies | Annals of Oncology | 2015 | 828 |
| Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma | New England Journal of Medicine | 2015 | 762 |
| Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update | Journal of Clinical Oncology | 2015 | 488 |
| Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy | Lancet Oncology, The | 2015 | 445 |
| Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer | Journal of Clinical Oncology | 2015 | 398 |
| STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade | Science Translational Medicine | 2015 | 396 |
| Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update | Journal of Clinical Oncology | 2015 | 363 |
| Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab | Journal of Clinical Oncology | 2015 | 337 |
| Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma | Cancer | 2015 | 334 |
| Sustained proliferation in cancer: Mechanisms and novel therapeutic targets | Seminars in Cancer Biology | 2015 | 321 |
| The genomic landscape of response to EGFR blockade in colorectal cancer | Nature | 2015 | 310 |
| Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer | Molecular Imaging and Biology | 2015 | 304 |
| Small cell lung cancer: where do we go from here? | Cancer | 2015 | 297 |
| The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients | Clinical Infectious Diseases | 2015 | 289 |
| Combination antifungal therapy for invasive aspergillosis: a randomized trial | Annals of Internal Medicine | 2015 | 286 |
| Personalized genomic analyses for cancer mutation discovery and interpretation | Science Translational Medicine | 2015 | 281 |
| Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients | Nature Communications | 2015 | 279 |
| Non-Small Cell Lung Cancer, Version 6.2015 | Journal of the National Comprehensive Cancer Network: JNCCN | 2015 | 268 |
